ClinicalTrials.gg
CompletedNCT07022977Updated Nov 12, 2026

A Study of MET233 in Individuals With Obesity or Overweight

A Phase 1 interventional study of MET233 and Placebo in Obesity and Overweight, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2024, registered Jun 2025).
Updated Nov 12, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Obesity by Pfizer — 13 open to participants now, 19 under way, 12 of them phase 3. Obesity · Pfizer.

Enrollment
29th of 62
145 · median 127
Started
2024
with 6 others
Phase 1
30 of 64
3 open now
Registered
44th of 64
by date

Among the 64 studies in Obesity by Pfizer, this one is the 29th largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2024, is one of 30 in phase 1, and was the 44th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 64 studies in Obesity by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Obesity by Pfizer, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity.

This study will be conducted in four parts:

  • Part A will evaluate single ascending doses of MET233 or placebo.
  • Part B will evaluate multiple ascending doses, with participants receiving five once-weekly doses of MET233 or placebo.
  • Part C will evaluate once-weekly dosing of MET233 or placebo for 12 weeks, followed by a single higher, potential monthly dose.
  • Part D will evaluate a longer dosing schedule, in which participants will receive twelve once-weekly doses, followed by three monthly doses of MET233 or placebo. Participants in this part will be followed for 14 weeks after the final dose.
Read the detailed description

This is a randomized, placebo-controlled, double-blind study designed to investigate the safety, tolerability, PK and pharmacodynamic (PD) of single and multiple ascending subcutaneous (SC) doses of MET233 in otherwise healthy adult participants with obesity or overweight (body mass index [BMI] 27.0 kg/m2 to 38.0 kg/m2, inclusive for Parts A-C and BMI in Part D 30- 45.0 kg/m2 (inclusive).

  • In Part A, participants will receive a single dose of MET233 at up to five dose levels.
  • In Part B, participants will receive five weekly doses of MET233 at up to four dose levels.
  • In Part C, participants will receive 12 weekly doses of MET233. These doses may include titration. For all cohorts in Part C, a 13th dose administered on Day 85 may be a monthly-equivalent dose to evaluate the potential for switching to a monthly dosing regimen.
  • In Part D, participants will receive 12 once-weekly doses, followed by three monthly doses of MET233 or placebo.
03

Conditions studied

  • Obesity and Overweight
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥18 to ≤70 years) male and female participants with obesity or overweight ( 27.0 kg/m2 to 38.0 kg/m2, inclusive) but otherwise healthy.

Exclusion criteria

Exclusion Criteria:

  • Female who is lactating or who is pregnant according to the pregnancy test at the Screening visit or prior to the first study drug administration
  • Seated blood pressure higher than 160/95 mmHg at the Screening visit
  • Elevated resting pulse greater than 100 beats per minute at Screening visit
  • Presence of abnormalities
  • Diagnosis of diabetes (type 1 or type 2)
  • Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration
  • Obesity induced by endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    (Part A) MET233

    Participants will receive a single dose of MET233 at up to 5 dose levels

    Biological: MET233

  • Placebo comparator
    (Part A) Placebo

    Participants will receive a single dose of placebo

    Biological: Placebo

  • Experimental
    (Part B) MET233

    Participants will receive five weekly doses of MET233 at up to 4 dose levels

    Biological: MET233

  • Placebo comparator
    (Part B) Placebo

    Participants will receive five weekly doses of placebo

    Biological: Placebo

  • Experimental
    (Part C) MET233

    Participants will receive twelve weekly doses of MET233 at up to 4 dose levels, followed by a 13th potential monthly dose

    Biological: MET233

  • Placebo comparator
    (Part C) Placebo

    Participants will receive twelve weekly doses of placebo, followed by a 13th potential monthly dose

    Biological: Placebo

  • Experimental
    (Part D) MET233

    Participants will receive twelve weekly doses of MET233, followed by three monthly doses.

    Biological: MET233

  • Placebo comparator
    (Part D) Placebo

    Participants will receive twelve weekly doses of placebo, followed by three monthly doses.

    Biological: Placebo

Interventions

  • BiologicalMET233

    For subcutaneous administration

  • BiologicalPlacebo

    Sterile 0.9% (w/v) saline for subcutaneous administration

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events

    Time frame: Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

Secondary outcomes

  1. Area under the concentration versus time curve extrapolated to infinity (AUCinf)

    Time frame: Part A (Baseline to Day 85)

  2. Area under the concentration versus time curve during the dosing interval (AUCtau)

    Time frame: Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

  3. Maximum observed concentration (Cmax)

    Time frame: Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

  4. Time to maximum observed concentration (Tmax)

    Time frame: Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

  5. Elimination half-life (t1/2)

    Time frame: Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

  6. Percent change from baseline in body weight at the protocol-specified weekly post-baseline measurements

    Time frame: Part A (Baseline to Day 85), Part B (Baseline to Day 113), Part C (Baseline to Day 162), Part D (Baseline to Day 239)

07

Study locations

1 site
  • Altasciences Clinical Los Angeles, Inc.
    Cypress, California 90630, United States
08

References and documents

Publications

  • Bailey CJ, Flatt PR, Conlon JM. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. 2026 Mar;196:171480. doi: 10.1016/j.peptides.2026.171480. Epub 2026 Feb 24. PubMed 41747885 ↗

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in May 2026, 18 months.

Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 18 months is above that.

Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Apr 2026 → May 2026 and completion Apr 2026 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 15, 2025
StartActual
Nov 7, 2024
Primary completionActual
May 28, 2026was Apr 2026
CompletionActual
May 28, 2026was Apr 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Nov 6, 2024→Nov 7, 2024
Nov 12, 2026
Primary completion
Apr 21, 2026→May 28, 2026
Nov 12, 2026
Study completion
Apr 21, 2026→May 28, 2026
Nov 12, 2026
Enrollment
144→145
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Nov 6, 2024→Nov 7, 2024
    Primary completion Apr 21, 2026→May 28, 2026
    Study completion Apr 21, 2026→May 28, 2026
    Enrollment 144→145
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07022977
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Nov 7, 2024
Primary completion
May 28, 2026
Completion
May 28, 2026
Last update
Nov 12, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion